Spaces:
Running
Running
Download NCT03178552.html from Umesh1608/biointel-reports: direct link, hf CLI and curl.
- Browser
- Download file 9.2 kB
-
https://huggingface.co/spaces/Umesh1608/biointel-reports/resolve/main/NCT03178552.html
- Command line
-
hf download hf://spaces/Umesh1608/biointel-reports/NCT03178552.html
-
curl -L -o NCT03178552.html https://huggingface.co/spaces/Umesh1608/biointel-reports/resolve/main/NCT03178552.html
9.2 kB
| <html lang="en"><head><meta charset="utf-8"> | |
| <meta name="viewport" content="width=device-width,initial-scale=1"> | |
| <title>NCT03178552 β A Study to Evaluate the Efficacy and Safety of Multiple Targeted Thera</title> | |
| <link rel="preconnect" href="https://fonts.googleapis.com"> | |
| <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet"> | |
| <style> | |
| *{box-sizing:border-box} | |
| body{margin:0;padding:32px 20px 60px;background:#F8FAFC;color:#0F172A; | |
| font:15px/1.6 Inter,ui-sans-serif,system-ui,-apple-system,sans-serif; | |
| -webkit-font-smoothing:antialiased} | |
| .wrap{max-width:900px;margin:0 auto} | |
| a{color:#0D9488} | |
| .eyebrow{font-size:.72rem;font-weight:600;letter-spacing:.09em; | |
| text-transform:uppercase;color:#64748B;margin-bottom:6px} | |
| h1{font-size:1.6rem;line-height:1.3;margin:0 0 10px;letter-spacing:-.02em} | |
| .meta{color:#64748B;font-size:.92rem;margin-bottom:22px} | |
| .meta b{color:#0F172A} | |
| .kpis{display:grid;grid-template-columns:repeat(auto-fit,minmax(130px,1fr)); | |
| gap:10px;margin:0 0 26px} | |
| .kpi{background:#fff;border:1px solid #E2E8F0;border-radius:12px;padding:12px 14px} | |
| .kpi .l{font-size:.67rem;font-weight:600;letter-spacing:.07em; | |
| text-transform:uppercase;color:#64748B} | |
| .kpi .v{font-size:1.35rem;font-weight:700;margin-top:3px; | |
| font-variant-numeric:tabular-nums;letter-spacing:-.01em} | |
| .kpi .s{font-size:.71rem;color:#94A3B8;margin-top:1px} | |
| section{background:#fff;border:1px solid #E2E8F0;border-radius:14px; | |
| padding:18px 20px;margin-bottom:16px} | |
| h2{font-size:1.02rem;margin:0 0 12px;letter-spacing:-.01em} | |
| table{width:100%;border-collapse:collapse;font-size:.9rem} | |
| td{padding:7px 0;border-bottom:1px solid #F1F5F9;vertical-align:top} | |
| td:first-child{color:#64748B;width:38%;padding-right:14px} | |
| tr:last-child td{border-bottom:none} | |
| .pill{display:inline-block;font-size:.74rem;font-weight:600;padding:3px 9px; | |
| border-radius:999px;background:#F1F5F9;color:#475569} | |
| .pill.good{background:#ECFDF5;color:#047857} | |
| .pill.warn{background:#FEF3C7;color:#92400E} | |
| .pill.bad{background:#FEF2F2;color:#B91C1C} | |
| .note{font-size:.86rem;color:#64748B;border-left:3px solid #0D9488; | |
| padding:4px 0 4px 12px;margin:12px 0 0} | |
| .pending{border-style:dashed;background:#FAFAF9} | |
| footer{color:#94A3B8;font-size:.78rem;margin-top:26px;line-height:1.7} | |
| ul{margin:6px 0 0;padding-left:18px}li{margin:3px 0} | |
| @media(prefers-color-scheme:dark){ | |
| body{background:#0B1120;color:#E2E8F0} | |
| .kpi,section{background:#131C2E;border-color:#263349} | |
| td{border-color:#1E293B}.meta b{color:#E2E8F0} | |
| .pill{background:#1E293B;color:#94A3B8} | |
| .pending{background:#0F1726} | |
| } | |
| </style></head><body><div class="wrap"> | |
| <div class="eyebrow">Pivotal trial dossier Β· BioIntel</div> | |
| <h1>A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)</h1> | |
| <div class="meta"><b>Hoffmann-La Roche</b> Β· Ph2/Ph3 Β· | |
| <a href="https://clinicaltrials.gov/study/NCT03178552" target="_blank" rel="noopener">NCT03178552</a> | |
| <span class='pill good'>exact date</span> <span class='pill warn'>enrolment is a target</span></div> | |
| <div class="kpis"><div class='kpi'><div class='l'>Readout due</div><div class='v'>2027-06-30</div><div class='s'>Ph2/Ph3</div></div><div class='kpi'><div class='l'>Patients</div><div class='v'>1,000</div><div class='s'>estimated</div></div><div class='kpi'><div class='l'>Sites</div><div class='v'>161</div><div class='s'>27 countries</div></div><div class='kpi'><div class='l'>Arms</div><div class='v'>11</div><div class='s'>randomized</div></div><div class='kpi'><div class='l'>Masking</div><div class='v'>None</div><div class='s'>blinding depth</div></div></div> | |
| <section><h2>Design</h2><table><tr><td>Allocation</td><td>Randomized</td></tr><tr><td>Masking</td><td>None</td></tr><tr><td>Primary purpose</td><td>Treatment</td></tr><tr><td>Arms</td><td>11</td></tr><tr><td>Planned duration</td><td>117 months</td></tr><tr><td>Started</td><td>2017-09-22</td></tr></table></section> | |
| <section><h2>What is being measured</h2><table><tr><td>Endpoint class</td><td><span class='pill '>survival</span></td></tr><tr><td>Primary outcomes</td><td>7</td></tr><tr><td>Stated as</td><td><i>Cohort A: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort B: Percentage of Participants with Confirmed Objective Response as Assessed by the Investigator Based on RECIST v1.1 | Cohort</i></td></tr></table> | |
| <div class="note">Endpoint class is inferred from the sponsor's own wording of | |
| the primary outcome. Hard endpoints such as survival are generally harder to | |
| hit than scales or laboratory surrogates.</div></section> | |
| <section><h2>Population</h2><table><tr><td>Condition</td><td>Non-Small Cell Lung Cancer</td></tr><tr><td>Therapeutic area</td><td><span class='pill '>oncology</span></td></tr><tr><td>Patient pre-selection</td><td><span class='pill '>all-comers (no selection detected)</span></td></tr><tr><td>Modality</td><td>cell_therapy</td></tr><tr><td>Sex</td><td>ALL</td></tr></table></section> | |
| <section><h2>Evidence trail</h2><table><tr><td>Linked references</td><td>4 on the registry record</td></tr><tr><td>Results posted</td><td><span class='pill '>not yet</span></td></tr><tr><td>Stopped early</td><td><span class='pill good'>no</span></td></tr></table></section> | |
| <section> | |
| <h2>Reference-class base rate</h2> | |
| <div style="font-size:2.3rem;font-weight:700;letter-spacing:-.02em;margin:2px 0 2px">34%</div> | |
| <div style="color:#64748B;font-size:.88rem;margin-bottom:14px"> | |
| historical share of Phase 3 trials in this class that reached approval</div> | |
| <div class="note"><b>This is a base rate, not a prediction about this trial.</b> | |
| It is what happened to comparable trials historically. It is not a model | |
| fitted on outcomes β no outcome labels exist for trials that have not read | |
| out β and it uses none of this trial's own results.</div> | |
| <h2 style="margin-top:18px">How this number was reached</h2> | |
| <ol style="font-size:.9rem;padding-left:20px"><li>Published Phase 3 β approval rate for oncology: 35.5% (Wong/Siah/Lo 2019) and 43.9% (BIO/Informa 2011β2020).</li><li>No biomarker selection detected. Oncology all-comer rate 33.6% replaces the band (biomarker-selected trials reach 63.6%).</li></ol> | |
| <h2 style="margin-top:18px">Design flags</h2> | |
| <ul style="font-size:.9rem;padding-left:20px;list-style:none"><li><span class='pill warn'>β’</span> Runs in 27 countries. Multi-country trials show higher termination odds (OR 0.65).</li></ul> | |
| <div class="note">Flags are shown separately rather than folded into the | |
| number. Wood et al. (BMJ 2008) measured effect-size inflation, not approval | |
| probability, so multiplying it into an approval rate would misuse the | |
| finding.</div> | |
| <h2 style="margin-top:18px">Deliberately not adjusted for</h2> | |
| <table><tr><td>Enrollment size</td><td>no evidenced association with Phase 3 success</td></tr><tr><td>Number of sites</td><td>no evidenced association</td></tr><tr><td>Endpoint type</td><td>no evidenced association with success once area is held</td></tr><tr><td>Phase 2 design</td><td>single-arm vs randomised Phase 2 does not predict Phase 3</td></tr></table> | |
| <div class="note">Each of these is visible in the registry and each is | |
| evidenced to be <b>null</b> for Phase 3 success. Using them would add | |
| false precision.</div> | |
| <h2 style="margin-top:18px">Evidenced, but not in the registry</h2> | |
| <table><tr><td>Sponsor approval track record</td><td>51%β81% (Danzon 2005) β not a registry field</td></tr><tr><td>Orphan designation</td><td>aOR 2.3 β zero CT.gov fields carry FDA designations</td></tr><tr><td>Phase 2 effect-size shrinkage</td><td>rHR 0.73 β requires prior-trial results</td></tr></table> | |
| <div class="note"><b>The standing criticism, stated plainly.</b> Hampson et al. | |
| (<i>Pharmaceutical Statistics</i> 2022;21(2):439β459, eight of nine authors at | |
| Novartis) argue that starting from industry rates and applying subjective | |
| adjustments "lacks transparency and fails to make full use of data from | |
| previous clinical trials". That criticism applies to this figure. The response | |
| here is to show every input and to refuse unsupported adjustments, not to | |
| claim the objection does not apply.</div> | |
| <div style="font-size:.78rem;color:#94A3B8;margin-top:12px"> | |
| Rates: Wong, Siah & Lo, <i>Biostatistics</i> 2019 (CC BY 4.0; corrigendum | |
| values) and BIO/Informa/QLS <i>Clinical Development Success Rates 2011β2020</i> | |
| (cited, not reproduced). MIT Project ALPHA is <b>not</b> used β its terms | |
| restrict use to governmental, charitable or social purposes and bar | |
| redistribution.</div> | |
| </section> | |
| <footer> | |
| Generated 19 Oct 2026 22:33 UTC by BioIntel from public sources. | |
| Trial data courtesy of the U.S. National Library of Medicine | |
| (ClinicalTrials.gov API v2), <b>modified</b>: therapeutic area, endpoint class | |
| and patient pre-selection are <b>inferred by this project</b> and are not | |
| registry fields. NLM does not endorse this reuse. SEC filings are public domain. | |
| <br><b>An information tool built on public filings. Not investment advice.</b> | |
| </footer></div></body></html> |